Jun 10, 2016 9:05 am EDT SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
Jun 8, 2016 4:05 pm EDT SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
May 13, 2016 8:00 am EDT SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections
May 9, 2016 9:25 am EDT SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
Apr 19, 2016 9:15 am EDT SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency
Apr 15, 2016 9:00 am EDT SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis
Apr 6, 2016 9:20 am EDT SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis
Mar 7, 2016 8:37 am EST SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update
Feb 29, 2016 5:30 pm EST SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference
